Revolution Medicines, Inc. Common Stock RVMD
i
Market dataready · fetched 2026-11-07T21:28:48.528Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T23:30:18.864500574Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T21:28:48.156161+00:00
Revolution Medicines, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 214.39 | 55.9% | 11.5% | 175.21 | 72.0% | 11.5% |
| 25Δ | 210.50 | 56.7% | 9.8% | 179.41 | 70.9% | 9.8% |
| 30Δ | 207.21 | 55.8% | 8.5% | 183.08 | 70.5% | 8.5% |
| 35Δ | 204.02 | 54.7% | 7.3% | 186.55 | 70.1% | 7.4% |
| 40Δ | 200.82 | 53.5% | 6.0% | 189.91 | 69.6% | 6.3% |
| 45Δ | 198.17 | 54.5% | 5.3% | 193.11 | 69.3% | 5.5% |
| 50Δ | 195.72 | 56.3% | 4.7% | 196.34 | 69.3% | 4.7% |
| 55Δ | 193.13 | 57.0% | 4.1% | 199.63 | 69.8% | 4.0% |
| 60Δ | 190.49 | 57.2% | 3.4% | 203.36 | 70.6% | 3.4% |
| 65Δ | 187.84 | 56.7% | 2.8% | 207.15 | 71.5% | 2.8% |
| 70Δ | 185.18 | 56.0% | 2.3% | 211.30 | 72.7% | 2.3% |
| 75Δ | 182.25 | 55.7% | 1.8% | 216.54 | 74.7% | 1.8% |
| 80Δ | 179.18 | 55.3% | 1.4% | 223.23 | 78.5% | 1.4% |
20Δ
- Pseudo strike
- 214.39
- IV
- 55.9%
- B/E move
- 11.5%
- Pseudo strike
- 175.21
- IV
- 72.0%
- B/E move
- 11.5%
25Δ
- Pseudo strike
- 210.50
- IV
- 56.7%
- B/E move
- 9.8%
- Pseudo strike
- 179.41
- IV
- 70.9%
- B/E move
- 9.8%
30Δ
- Pseudo strike
- 207.21
- IV
- 55.8%
- B/E move
- 8.5%
- Pseudo strike
- 183.08
- IV
- 70.5%
- B/E move
- 8.5%
35Δ
- Pseudo strike
- 204.02
- IV
- 54.7%
- B/E move
- 7.3%
- Pseudo strike
- 186.55
- IV
- 70.1%
- B/E move
- 7.4%
40Δ
- Pseudo strike
- 200.82
- IV
- 53.5%
- B/E move
- 6.0%
- Pseudo strike
- 189.91
- IV
- 69.6%
- B/E move
- 6.3%
45Δ
- Pseudo strike
- 198.17
- IV
- 54.5%
- B/E move
- 5.3%
- Pseudo strike
- 193.11
- IV
- 69.3%
- B/E move
- 5.5%
50Δ
- Pseudo strike
- 195.72
- IV
- 56.3%
- B/E move
- 4.7%
- Pseudo strike
- 196.34
- IV
- 69.3%
- B/E move
- 4.7%
55Δ
- Pseudo strike
- 193.13
- IV
- 57.0%
- B/E move
- 4.1%
- Pseudo strike
- 199.63
- IV
- 69.8%
- B/E move
- 4.0%
60Δ
- Pseudo strike
- 190.49
- IV
- 57.2%
- B/E move
- 3.4%
- Pseudo strike
- 203.36
- IV
- 70.6%
- B/E move
- 3.4%
65Δ
- Pseudo strike
- 187.84
- IV
- 56.7%
- B/E move
- 2.8%
- Pseudo strike
- 207.15
- IV
- 71.5%
- B/E move
- 2.8%
70Δ
- Pseudo strike
- 185.18
- IV
- 56.0%
- B/E move
- 2.3%
- Pseudo strike
- 211.30
- IV
- 72.7%
- B/E move
- 2.3%
75Δ
- Pseudo strike
- 182.25
- IV
- 55.7%
- B/E move
- 1.8%
- Pseudo strike
- 216.54
- IV
- 74.7%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- 179.18
- IV
- 55.3%
- B/E move
- 1.4%
- Pseudo strike
- 223.23
- IV
- 78.5%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 53.99% | |
| 52.96% | |
| 52.60% | |
| 51.37% | |
| 51.48% | |
| 53.71% | |
| 52.14% | |
| 53.79% | |
| 55.85% | |
| 50.79% | |
| 48.79% | |
| 49.64% | |
| 49.19% | |
| 48.38% | |
| 49.98% | |
| 49.66% | |
| 48.40% | |
| 48.12% | |
| 48.63% | |
| 48.67% | |
| 50.08% | |
| 49.72% | |
| 48.52% | |
| 47.18% | |
| 49.69% | |
| 49.63% | |
| 49.78% | |
| 52.51% | |
| 46.59% | |
| 47.05% | |
| 46.65% | |
| 46.35% | |
| 46.97% | |
| 47.40% | |
| 48.77% | |
| 48.30% | |
| 48.13% | |
| 46.75% | |
| 47.31% | |
| 46.50% | |
| 45.62% | |
| 46.16% | |
| 52.77% | |
| 49.94% | |
| 51.52% | |
| 55.25% | |
| 54.35% | |
| 56.13% | |
| 54.42% | |
| 53.39% | |
| 55.46% | |
| 55.14% | |
| 56.85% | |
| 56.66% | |
| 57.99% | |
| 57.02% | |
| 55.92% | |
| 55.86% | |
| 57.05% |
Biotechnology
RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data…
More →RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic…
More →RZLT
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City,…
More →SABS
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in…
More →SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
More →SEPN
Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. The company combines…
More →